Cinfa launches Olmedine HCT in the UAE for the treatment
of high blood pressure
(UAE) - The European pharmaceutical laboratory
Cinfa has launched its
new product Olmedine HCT to
control high blood pressure.
Hypertension (HTN) is one of
the non-communicable
diseases whose prevalence is
increasing in both developed
and developing countries.
Cinfa has made this launch
in response to it in the
Middle East, a region where
this disease has become a
major public health
challenge, according to the
Ministry of Health of the
United Arab Emirates.
The new product is
composed of Olmesartan
medoxomil, Amlodipine (as
amlodipine besylate) and
Hydrochlorothiazide, three
molecules available in
different doses
(20mg/12.5mg/5mg),
(40mg/10mg/12.5mg),
(40mg/10mg/25mg),
(40mg/5mg/12.5mg),
(40mg/5mg/25mg).
Dr.
Alicia López de Ocariz,
Corporate Medical Director
at Cinfa Group, has
emphasized the importance of
preventing cardiovascular
diseases, and highlighted
that “80% of cardiovascular
diseases are preventable,
therefore, it is essential
that society is aware that
their lifestyle affects
their health”.
And
added that, “five major risk
factors for cardiovascular
diseases are high blood
pressure, high levels of
low-density lipoprotein
[LDL] cholesterol, low
levels of high-density
lipoprotein [HDL]
cholesterol, high fasting
glucose level and smoking.
Family history is an
independent risk factor,
particularly among younger
individuals with a family
history of premature
disease”.
Use
of Olmedine HCT
Olmedine HCT is used as
a treatment for adult
patients whose blood
pressure is not sufficiently
controlled with the
combination of two of these
three molecules. In
addition, it is used in
patients who are already
taking a combination of
olmesartan medoxomil and
hydrochlorothiazide together
with amlodipine but not in
one single tablet. The use
of Olmedine HCT is a
rational approach for
achieving optimal
therapeutic benefits while
minimizing pill burden,
especially important in
chronic diseases such as
hypertension. Greater
convenience with decreased
pill burden leads to
improved adherence,
resulting in superior
clinical outcomes and
greater
cost-effectiveness. The
different and multiple
dosages of Omedine HCT allow
dosage flexibility and dose
titration.
Composition of the medicine
This medication
is a compound by three
active substances:
-
Olmesartan medoxomil: is an angiotensin-II receptor
antagonist. which blocks
the vasoconstrictor and
aldosterone-secreting
effects of angiotensin
II.
-
Amlodipine (as amlodipine besilate): is a calcium channel
blocker. This substance
directly acts on
vascular smooth muscle
to produce peripheral
arterial vasodilation
reducing peripheral
vascular resistance and
blood pressure.
-
Hydrochlorothiazide: is a thiazide diuretic. The hypotensive
response is mediated by
a reduction in plasma
volume and cardiac
output.
REFERENCES:
Prevalence, awareness, treatment and control of
hypertension in four Middle
East countries
https://mohap.gov.ae/en/media-center/news/9/6/2022/mohap-to-intensify-efforts-to-reduce-hypertension-prevalence-in-the-uae.
Systematic review and
meta-analysis: Prevalence of
hypertension among
adolescents in the Arab
countries
https://www.sciencedirect.com/science/article/abs/pii/S0882596322000641.
